The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: FTSE 100 falls at end of tepid week

Fri, 09th Feb 2024 17:02

(Alliance News) - Stock prices in London closed lower on Friday, with the FTSE 100's losing streak extending to three days, as sentiment in Europe remains tetchy despite a largely stellar start to the day in New York.

The divergence between markets in Europe and New York was perhaps typified by the S&P 500 hitting a record high, cementing its status above the 5,000 point threshold.

The greenback ended the week by returning gains, meanwhile, as a government release denoting consumer price index reading revisions offered little to dollar bulls.

The FTSE 100 index closed down 22.90 points, 0.3%, at 7,572.58. The FTSE 250 ended 40.40 points lower, 0.2%, at 19,062.32, and the AIM All-Share lost 3.69 points, 0.5%, at 747.41.

For the week, both the FTSE 100 and FTSE 250 lost 0.6%, while the AIM All-Share gave back 0.9%

The Cboe UK 100 ended down 0.3% at 756.87, the Cboe UK 250 fell 0.5% to 16,463.05, and the Cboe Small Companies lost 0.3% to 14,534.93.

In European equities on Friday, both the CAC 40 in Paris and the DAX 40 in Frankfurt ended down 0.2%.

In New York, the Dow Jones Industrial Average was down 0.13%, while the S&P 500 added 0.3% and the Nasdaq Composite surged 0.9%.

Having very briefly topped the threshold on Thursday, the S&P 500 opened above 5,000 points on Friday.

"While the Nasdaq 100 and S&P 500 are making new record highs, the latter topping the 5,000 mark, European stock indices found it difficult to keep up and have had a slightly negative end to the week. The FTSE 100 in particular suffered a third straight day of losses ahead of next week's UK unemployment, inflation, Q4 GDP and retail sales data," IG analyst Axel Rudolph commented.

The unemployment, inflation and economic growth readings will be closely eyed by the Bank of England, with the next interest rate decision from Threadneedle Street around six weeks away.

The UK inflation data is released on Wednesday, though there is another reading before the BoE's next decision on March 20.

US inflation data for January is released on Tuesday. According to consensus cited by FXStreet, the annual consumer price inflation rate is expected to have cooled to 3.0% in January, from 3.4% in December.

US inflation data from the end of last year saw little in the way of revisions, according to new data published Friday.

The Bureau of Labor Statistics made minimal revisions to last year's inflation data, with consumer prices excluding food and energy items rising at a 3.3% annualised rate in the final three months of 2023, matching the previous reading.

Revisions to the headline figure were also minimal. December's monthly increase was marked down to a 0.2% advance instead of 0.3%, while the reading for November moved up 0.1 percentage point, also to 0.2%.

The dollar fell back after the figures, which were seen as supporting an interest rate cut in May.

Federal Reserve Chair Jerome Powell and his colleagues have said they need to see more evidence that price pressures are sustainably receding before they begin cutting interest rates.

In late January, Powell eroded hopes for a cut in interest rates in March, saying it is not the "most likely case."

The pound was quoted at USD1.2632 late on Friday in London, up compared to USD1.2609 at the equities close on Thursday. The euro stood at USD1.0783, up against USD1.0763. Against the yen, the dollar was trading at JPY149.31, down from JPY149.39.

In London, there was little in the way of major large-cap moves, with Fresnillo closing among the worst FTSE 100 performers. The gold miner ended down 3.4%, tracking bullion prices lower.

"After a barrage of company announcements this week, it's no wonder that markets have paused for breath on Friday. Investors have had so much to take in from a wealth of big names that they're exhausted by the all the numbers," AJ Bell analyst Russ Mould commented.

Gold was quoted at USD2,021.73 an ounce late Friday afternoon, down against USD2,029.31 late Thursday and off the USD2,034.63 it fetched this time last week. Gold traded as low as below the USD2,015 mark earlier this week.

ACY Securities analyst Luca Santos commented: "Gold, the age-old symbol of wealth and stability, has recently faced a significant challenge, breaking below a crucial technical support level at USD2.017 per ounce. This development sends a negative signal for both gold and silver. There is even a possibility of a further slide to the mid USD1.980 per ounce level, indicating a challenging period for gold investors."

Recently the object of takeover interest, packaging firm DS Smith and housebuilder Redrow climbed 2.5% and 0.3%, extending gains. Peer Mondi is mulling a takeover of DS Smith, while Redrow has agreed to a housebuilding tie-up with Barratt Developments.

There was some more dealmaking on Friday.

Barclays is to buy the retail banking business of Tesco Bank, as the big UK supermarkets scale back their forays into financial services.

Tesco said it will sell to Barclays all of its banking operations in credit cards, loans and savings to Barclays, while retaining other activities of Tesco Bank including insurance, automatic teller machines, travel money and gift cards. The supermarket noted that these businesses are capital-light, profitable, and have a strong connect to its core retail offer.

Barclays will pay about GBP600 million for the business, which has been in operation for more than 25 years. Tesco noted it will receive about GBP1 billion in cash in total, including a special dividend of GBP250 million paid by Tesco Bank back in August.

Tesco shares closed marginally higher, while Barclays fell 0.6% in a tricky day for London-listed lenders.

HSBC shares fell 1.3%, weighing on the FTSE 100. NatWest, meanwhile, gave back 2.2%, before it reports annual results next week Friday.

Elsewhere in London, AIM-listed Evgen Pharma slumped 22% as it announced it has issued a notice of dispute with partner Stalicla, explaining that it has not received funds it believes it is entitled to.

"In October 2022, Evgen licensed the global rights for lead asset SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla for up to USD160.5 million in milestone payments. An initial USD500,000 was paid upfront with the next anticipated payment of USD500,000 due on completion of the Evgen-sponsored human volunteer Phase 1 study.

"The phase 1b human volunteer study was completed and the clinical study report finalised in August 2023."

Evgen said it believes the "payment is now due".

"In order to effect the payment, Evgen has taken the decision to formally implement the dispute resolution process detailed in the License Agreement, the first step of which is the issuance of a dispute notice. As stated in the half year results in October 2023, Evgen has not anticipated any milestone payments from Stalicla in its financial forecasting and its cash runway remains unchanged," it added.

Brent oil was quoted at USD82.03 a barrel late in London on Friday, up from USD81.02 late Thursday.

On Monday, financial markets in Shanghai and Tokyo are closed for the Chinese New Year and National Day holidays, respectively.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
22 Mar 2021 14:32

IN BRIEF: Evgen Pharma names Helen Kuhlman as chief business officer

IN BRIEF: Evgen Pharma names Helen Kuhlman as chief business officer

Read more
22 Mar 2021 09:08

Evgen appoints Helen Kuhlman as chief business officer

(Sharecast News) - Clinical-stage drug development company Evgen announced on Monday that Helen Kuhlman had been appointed to the post of chief business officer, taking up the role from 1 April.

Read more
11 Mar 2021 20:08

IN BRIEF: Evgen says no patient safety concerns in STAR Covid-19 trial

IN BRIEF: Evgen says no patient safety concerns in STAR Covid-19 trial

Read more
11 Mar 2021 15:12

Evgen Covid-19 trial given all-clear on safety and data

(Sharecast News) - Clinical stage drug development company Evgen Pharma announced on Thursday that after a review of the first 60 patients enrolled, the data safety monitoring committee for the 'STAR' Covid-19 trial had concluded that there were no concerns over patient safety or data quality that would prevent its continuation.

Read more
3 Mar 2021 20:16

TRADING UPDATES: Cambria drives on amid virus; Argo crypto mining up

TRADING UPDATES: Cambria drives on amid virus; Argo crypto mining up

Read more
24 Feb 2021 16:09

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
17 Feb 2021 15:10

Evgen makes progress with recruitment in 'STAR' trial

(Sharecast News) - Clinical stage drug development company Evgen Pharma said on Wednesday that a total of 102 patients had been recruited and randomised to the 'STAR', or 'SFX-01 Treatment for Acute Respiratory infections', trial.

Read more
17 Feb 2021 11:15

IN BRIEF: Evgen Pharma Recruits Over 100 For Respiratory Drug Trial

IN BRIEF: Evgen Pharma Recruits Over 100 For Respiratory Drug Trial

Read more
3 Feb 2021 11:49

IN BRIEF: Intuitive Investments Buys Shares in Evgen For GBP175,000

IN BRIEF: Intuitive Investments Buys Shares in Evgen For GBP175,000

Read more
2 Feb 2021 17:45

IN BRIEF: Evgen Pharma's GBP11 Fundraise To Support Lead Candidate

IN BRIEF: Evgen Pharma's GBP11 Fundraise To Support Lead Candidate

Read more
22 Jan 2021 08:53

Evgen Shares Rise On Further Positive Test Results For SFX-01

Evgen Shares Rise On Further Positive Test Results For SFX-01

Read more
21 Jan 2021 13:20

IN BRIEF: Evgen Pharma Notes Positive Preclinical Data For SFX-01

IN BRIEF: Evgen Pharma Notes Positive Preclinical Data For SFX-01

Read more
19 Jan 2021 17:34

IN BRIEF: Evgen Pharma Recruits Patients For STAR-Covid-19 Trial

IN BRIEF: Evgen Pharma Recruits Patients For STAR-Covid-19 Trial

Read more
10 Dec 2020 17:07

UK EARNINGS SUMMARY: Character Group Lowers Dividend As Profit Drops

UK EARNINGS SUMMARY: Character Group Lowers Dividend As Profit Drops

Read more
10 Dec 2020 15:45

Evgen Pharma performs in line with forecasts in first half

(Sharecast News) - Clinical-stage drug development company Evgen Pharma reported financial performance in line with its expectations in its first half on Thursday, with revenue coming in at £0.19m, compared to nil a year earlier.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.